Plain-English translation of NCT00001465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study designed to help doctors understand how lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women, damages the lungs at a cellular and molecular level. By studying people with LAM and comparing them to healthy volunteers, researchers hope to identify the proteins and genes involved in the disease. This knowledge could eventually lead to better treatments.
Currently, there is no proven effective treatment for LAM, and the disease progresses unpredictably in different patients. This study exists to fill that gap by understanding exactly what happens inside the lungs during this disease, so that doctors can develop more effective therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be admitted for evaluation visits every six months or more often if needed for research purposes. During these visits, you would complete tests such as lung function tests, imaging scans, exercise tests, and possibly donate tissue or fluid samples. Pregnant or nursing participants can join, but certain procedures involving radiation or contrast dye would be postponed until after pregnancy or nursing ends.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~2,000 participants
Started
December 1995
Age range
16 Years – 100 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tatyana A Worthy, R.N.
National Heart, Lung, and Blood Institute (NHLBI)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.